InspireMD, Inc. (NYSE:NSPR – Get Free Report) CEO Marvin Slosman purchased 21,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were purchased at an average price of $1.20 per share, for a total transaction of $25,200.00. Following the completion of the acquisition, the chief executive officer owned 3,556,658 shares of the company’s stock, valued at $4,267,989.60. The trade was a 0.59% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
InspireMD Stock Down 2.5%
InspireMD stock traded down $0.03 during midday trading on Wednesday, hitting $1.17. 323,560 shares of the stock were exchanged, compared to its average volume of 181,792. InspireMD, Inc. has a 52-week low of $1.02 and a 52-week high of $2.93. The stock has a market capitalization of $54.80 million, a price-to-earnings ratio of -1.56 and a beta of 0.82. The business’s 50-day moving average price is $1.47 and its 200-day moving average price is $1.73.
Institutional Trading of InspireMD
Hedge funds have recently added to or reduced their stakes in the stock. Ghisallo Capital Management LLC bought a new stake in InspireMD in the third quarter worth about $2,221,000. Aberdeen Group plc bought a new stake in shares of InspireMD in the third quarter valued at approximately $5,979,000. Rosalind Advisors Inc. raised its position in shares of InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock valued at $9,413,000 after purchasing an additional 1,616,644 shares during the period. Citadel Advisors LLC raised its position in shares of InspireMD by 45.0% in the third quarter. Citadel Advisors LLC now owns 37,954 shares of the company’s stock valued at $91,000 after purchasing an additional 11,778 shares during the period. Finally, Creative Planning bought a new stake in shares of InspireMD in the second quarter valued at approximately $44,000. Institutional investors own 44.78% of the company’s stock.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on InspireMD
About InspireMD
InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.
The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.
Further Reading
- Five stocks we like better than InspireMD
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.
